Second-generation BCR-ABL kinase inhibitors in CML [3]

New England Journal of Medicine

Volumn 363, Issue 17, 2010, Pages 1673-

  Beyazit, Yavuz ^a   Kekilli, Murat ^a   Haznedaroglu, Ibrahim C ^b  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE; DRUG ANTAGONISM; MYELOID LEUKEMIA; NOTE; REMISSION;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; THIAZOLES;

EID: 77958564524     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51.
2. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia- positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009;113:4497-504.
3. Haznedaroglu IC, Koca E, Aksu S, et al. Imatinib shall be removed from the ELN-CML recommendations. Int J Hematol Oncol 2010;20:Suppl 1:25-6. abstract.